Table 2.
The designs of PROFILE 1001, 1005, 1007, 1014, and 1029
| NCT identifier | Other ID numbers | Phase | Line | Population | Chinese included or not | Target | Convention |
|---|---|---|---|---|---|---|---|
| NCT00585195 | PROFILE 1001 | I | Any line | Global | No | ALK/c-Met/ROS1 | Crizotinib |
| NCT00932451 | PROFILE 1005 | II | ≥2 | Global | Yes | ALK | Crizotinib |
| NCT00932893 | PROFILE 1007 | III | 2 | Global | Yes | ALK | Crizotinib vs pemetrexed/docetaxel |
| NCT01154140 | PROFILE 1014 | III | 1 | Global | Yes | ALK | Crizotinib vs PC/PP |
| NCT01639001 | PROFILE 1029 | III | 1 | East Asian | Yes | ALK | Crizotinib vs PC/PP |
Abbreviations: PC, pemetrexed plus carboplatin; PP, pemetrexed plus cisplatin.